Business Wire
03 Mar 2026, 15:00 UTC · 29w ago
Verdict
Headline takes no side. We score PRVA +0.60 across one claim — strongly bullish.
+0.60strongly bullish
More positive than 75% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish
A collaborative colorectal cancer screening program involving Amalgam Rx, Privia Health, and Exact Sciences successfully increased screening rates.
More positive than 64% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 75% of ticker scores this week
Successfully led a colorectal cancer screening program that demonstrated an increase in screening rates.
More positive than 65% of ticker scores this week
Supported a successful clinical screening program, reflecting positive utility of their products.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Globe News Wire
4h ago
−19.1%
Price is moving against the score
$19.46 vs $24.04 close before publication (Mar 2) · not market-adjusted
PRVA chart →
